10X Capital Venture Acquisition III (10X Capital Venture Acquisition III) Cash And Cash Equivalents : $0.65 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is 10X Capital Venture Acquisition III Cash And Cash Equivalents?

10X Capital Venture Acquisition III's quarterly cash and cash equivalents increased from Mar. 2023 ($0.03 Mil) to Jun. 2023 ($1.96 Mil) but then stayed the same from Jun. 2023 ($1.96 Mil) to Sep. 2023 ($0.65 Mil).

10X Capital Venture Acquisition III's annual cash and cash equivalents stayed the same from . 20 ($0.00 Mil) to Dec. 2021 ($0.00 Mil) but then increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.07 Mil).

10X Capital Venture Acquisition III Cash And Cash Equivalents Historical Data

The historical data trend for 10X Capital Venture Acquisition III's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10X Capital Venture Acquisition III Cash And Cash Equivalents Chart

10X Capital Venture Acquisition III Annual Data

Trend

Dec21

Dec22

Cash And Cash Equivalents

0.07

10X Capital Venture Acquisition III Quarterly Data
	Feb21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash And Cash Equivalents	Get a 7-Day Free Trial						0.13	0.07	0.03	1.96	0.65

10X Capital Venture Acquisition III Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

10X Capital Venture Acquisition III (AMEX:VCXBU) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

10X Capital Venture Acquisition III Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of 10X Capital Venture Acquisition III's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

10X Capital Venture Acquisition III (10X Capital Venture Acquisition III) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » 10X Capital Venture Acquisition Corp III (AMEX:VCXBU) » Definitions » Cash And Cash Equivalents

Comparable Companies

BCSA LCW GAQ FLME CHEA EVE HCMA SUAC ALCY HHLA PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA

Traded in Other Exchanges

VCXB:USA

Address

1 World Trade Center, 85th Floor, New York, NY, USA, 10007

Website

https://www.10xspac.com

10X Capital Venture Acquisition Corp III is a blank check company.

10X Capital Venture Acquisition III (10X Capital Venture Acquisition III) Headlines

From GuruFocus

Correction: Addimmune, a Clinical Stage HIV-Focused Gene Therapy Company, to go Public Through Business Combination With 10X Capital Venture Acquisition Corp. III

By GlobeNewswire • 08-10-2023